Insights

Clinical-Stage Biopharma Bionomics is a clinical-stage biopharmaceutical company specializing in developing novel ion channel modulators for serious CNS disorders, presenting an opportunity for collaboration and partnership in advancing patient care.

Strategic Partnership with Merck & Co. The strategic partnership with Merck & Co., Inc. for drugs targeting cognitive deficits in Alzheimer's disease offers a potential avenue for expanding market reach and leveraging expertise in CNS conditions.

Innovative Product Pipeline With a lead product candidate, BNC210, addressing Social Anxiety Disorder and Post-Traumatic Stress Disorder, there is a sales opportunity for healthcare providers seeking novel treatments in mental health.

Financial Growth Potential Despite current revenue being in the range of $0 - 10M, recent funding of $5M signals potential growth possibilities, attracting investors looking to capitalize on biotech innovations.

Competitive Positioning with ERM Compared to similar companies like ERM with substantial revenue and employee base, Bionomics' focused approach on CNS disorders offers a niche market advantage and sales differentiation.

Similar companies to Bionomics Ltd

ERM
10K$1B

Bionomics Ltd Tech Stack

Bionomics Ltd uses 8 technology products and services including MySQL, Google Font API, React, and more. Explore Bionomics Ltd's tech stack below.

MySQL
Database
Google Font API
Font Scripts
React
Javascript Frameworks
jQuery UI
Javascript Libraries
Webpack
Miscellaneous
Akamai Bot Manager
Security
Acquia Cloud Site Factory
Web Hosting
IIS
Web Servers

Media & News

Bionomics Ltd's Email Address Formats

Bionomics Ltd uses at least 1 format(s):

Bionomics Ltd Email Formats	Example	Percentage
FLast@bionomics.com.au	JDoe@bionomics.com.au	50%
FLast@bionomics.com.au	JDoe@bionomics.com.au	50%

Frequently Asked Questions

Where is Bionomics Ltd's headquarters located?

Bionomics Ltd's main headquarters is located at 200 Greenhill Rd Eastwood, South Australia 5063 AU. The company has employees across 4 continents, including OceaniaNorth AmericaEurope.

What is Bionomics Ltd's phone number?

You can contact Bionomics Ltd's main corporate office by phone at

+61-8-8354-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Bionomics Ltd's official website and social media links?

Bionomics Ltd's official website is bionomics.com.au and has social profiles on LinkedIn.

How much revenue does Bionomics Ltd generate?

As of October 2023, Bionomics Ltd's annual revenue reached $3.8M.

What is Bionomics Ltd's SIC code NAICS code?

Bionomics Ltd's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Bionomics Ltd have currently?

As of October 2023, Bionomics Ltd has approximately 27 employees across 4 continents, including OceaniaNorth AmericaEurope. Key team members include Chief Medical Officer: B. C.Chief Medical Officer: P. R.Vice President | Business Development & Scientific Evaluation: M. B.. Explore Bionomics Ltd's employee directory with LeadIQ.

What industry does Bionomics Ltd belong to?

Bionomics Ltd operates in the Biotechnology Research industry.

What technology does Bionomics Ltd use?

Bionomics Ltd's tech stack includes MySQLGoogle Font APIReactjQuery UIWebpackAkamai Bot ManagerAcquia Cloud Site FactoryIIS.

What is Bionomics Ltd's email format?

Bionomics Ltd's email format typically follows the pattern of . Find more Bionomics Ltd email formats with LeadIQ.

How much funding has Bionomics Ltd raised to date?

As of October 2023, Bionomics Ltd has raised $5M in funding. The last funding round occurred on Nov 21, 2022 for $5M.

Bionomics Ltd

Biotechnology ResearchSouth Australia, Australia11-50 Employees

Bionomics (Nasdaq: BNOX, ASX:BNO) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder.

Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions. 

To learn more about the company, pipeline and collaboration opportunities, visit us at www.bionomics.com.au.

Company Overview

Headquarters: 200 Greenhill Rd Eastwood, South Australia 5063 AU
Phone number: +61-8-8354-****
Website: bionomics.com.au
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 11-50

Media & News

Funding & Financials

$5M
Bionomics Ltd has raised a total of $5M of funding over 5 rounds. Their latest funding round was raised on Nov 21, 2022 in the amount of $5M.
$10M
Bionomics Ltd's revenue is in the range of $10M

Funding & Financials

$5M
Bionomics Ltd has raised a total of $5M of funding over 5 rounds. Their latest funding round was raised on Nov 21, 2022 in the amount of $5M.
$10M
Bionomics Ltd's revenue is in the range of $10M